THU247 Characterizing Inpatient Cases Of DKA Precipitated By SGLT2 Inhibitor Use

Disclosure: A. Aslamy: None. R. Nazemi: Speaker; Self; Eli Lilly & Company, AstraZeneca. C. Tseng: None. S. Kim: None. R. Gianchandani: None. Background: SGLT2 inhibitors are a unique class of anti-hyperglycemic medications that can increase the risk of DKA in patients with diabetes (1). The ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Aslamy, Arianne, Nazemi, Reza, Tseng, Conrad, Kim, Steve, Gianchandani, Roma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Diabetes And Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554664/
http://dx.doi.org/10.1210/jendso/bvad114.684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554664/
http://dx.doi.org/10.1210/jendso/bvad114.684

Ejemplares similares